(Q35688316)

English

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

scientific article published on 15 November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme (English)

1 reference

Europe PubMed Central

9 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Karla V Ballman

1

1 reference

Europe PubMed Central

9 August 2017

Jan C Buckner

2

1 reference

Europe PubMed Central

9 August 2017

Paul D Brown

3

1 reference

Europe PubMed Central

9 August 2017

Caterina Giannini

4

1 reference

Europe PubMed Central

9 August 2017

Patrick J Flynn

5

1 reference

Europe PubMed Central

9 August 2017

Betsy R LaPlant

6

1 reference

Europe PubMed Central

9 August 2017

Kurt A Jaeckle

7

1 reference

Europe PubMed Central

9 August 2017

publication date

15 November 2006

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

9

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

29-38

1 reference

Europe PubMed Central

9 August 2017

Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

A perfect correlate does not a surrogate make

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Clinical trials in neuro-oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Response and progression in recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Clinical trial end points in malignant glioma: need for effective trial design strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

On the relationship between response to treatment and survival time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Evaluation of fludarabine phosphate in patients with recurrent glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

12 July 2018

Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

27 July 2018

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Phase II North Central Cancer Treatment Group study of 2-cholorodeoxyadenosine in patients with recurrent glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1828103

25 September 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1215%2F15228517-2006-025

21 January 2018

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17108063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of amonafide in patients with recurrent glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17108063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17108063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1215/15228517-2006-025

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35688316&oldid=1583686325"